dc.contributor.author | Eguren, Manuel | |
dc.contributor.author | Alvarez Fernandez, Monica | |
dc.contributor.author | García, Fernando | |
dc.contributor.author | López-Contreras, Andrés J | |
dc.contributor.author | Fujimitsu, Kazuyuki | |
dc.contributor.author | Yaguchi, Hiroko | |
dc.contributor.author | Luque-García, José Luis | |
dc.contributor.author | Yamano, Hiroyuki | |
dc.contributor.author | Fernandez-Capetillo, Oscar | |
dc.contributor.author | Malumbres Martinez, Marcos | |
dc.contributor.author | Munoz, Javier | |
dc.date.accessioned | 2020-11-23T11:47:39Z | |
dc.date.available | 2020-11-23T11:47:39Z | |
dc.date.issued | 2014-02-27 | |
dc.identifier.citation | Cell Rep. 2014 ;6(4):670-83. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/11399 | |
dc.description.abstract | The Anaphase-promoting complex/cyclosome (APC/C) cofactor Cdh1 modulates cell proliferation by targeting multiple cell-cycle regulators for ubiquitin-dependent degradation. Lack of Cdh1 results in structural and numerical chromosome aberrations, a hallmark of genomic instability. By using a proteomic approach in Cdh1-null cells and mouse tissues, we have identified kinesin Eg5 and topoisomerase 2α as Cdh1 targets involved in the maintenance of genomic stability. These proteins are ubiquitinated and degraded through specific KEN and D boxes in a Cdh1-dependent manner. Whereas Cdh1-null cells display partial resistance to Eg5 inhibitors such as monastrol, lack of Cdh1 results in a dramatic sensitivity to Top2α poisons as a consequence of increased levels of trapped Top2α-DNA complexes. Chemical inhibition of the APC/C in cancer cells results in increased sensitivity to Top2α poisons. This work identifies in vivo targets of the mammalian APC/C-Cdh1 complex and reveals synthetic lethal interactions of relevance in anticancer treatments. | es_ES |
dc.description.sponsorship | We thank Angeles Almeida, Thomas U. Mayer, William T. Beck, Anthony A. Hyman, Jan-Michael Peters, Eusebio Manchado, and Scott Lowe for reagents. M. E., A.J.L.-C., and M.A.-F. were supported by the Spanish Ministry of Education, Culture and Sports, the AECC Scientific Foundation, and the EU-PEOPLE programme, respectively. Work in the O.F.-C. laboratory was supported by grants from the Spanish Ministry of Economy and Competitiveness (MINECO; SAF2011-23753), the Association for International Cancer Research (120229), the Howard Hughes Medical Institute, and the European Research Council (ERC-210520). Work in the H.Y. laboratory was funded by grants from Marie Curie Cancer Care and Cancer Research UK. Work in M.M.'s laboratory was funded by grants from the Foundation Ramon Areces, MINECO (SAF2012-38215), the OncoCycle Programme (S2010/BMD-2470) from the Comunidad de Madrid, and the European Union Seventh Framework Programme (MitoSys project; HEALTH-F5-2010-241548). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Cell Press | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | * |
dc.subject.mesh | Animals | es_ES |
dc.subject.mesh | Antigens, Neoplasm | es_ES |
dc.subject.mesh | Binding Sites | es_ES |
dc.subject.mesh | Cdh1 Proteins | es_ES |
dc.subject.mesh | DNA Topoisomerases, Type II | es_ES |
dc.subject.mesh | DNA-Binding Proteins | es_ES |
dc.subject.mesh | Genomic Instability | es_ES |
dc.subject.mesh | HEK293 Cells | es_ES |
dc.subject.mesh | HeLa Cells | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Kinesin | es_ES |
dc.subject.mesh | Mice | es_ES |
dc.subject.mesh | Protein Binding | es_ES |
dc.subject.mesh | Proteome | es_ES |
dc.subject.mesh | Pyrimidines | es_ES |
dc.subject.mesh | Thiones | es_ES |
dc.subject.mesh | Topoisomerase II Inhibitors | es_ES |
dc.subject.mesh | Ubiquitination | es_ES |
dc.subject.mesh | Xenopus | es_ES |
dc.title | A synthetic lethal interaction between APC/C and topoisomerase poisons uncovered by proteomic screens. | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución-NoComercial-CompartirIgual 4.0 Internacional | * |
dc.identifier.pubmedID | 24508461 | es_ES |
dc.format.volume | 6 | es_ES |
dc.format.number | 4 | es_ES |
dc.format.page | 670-83 | es_ES |
dc.identifier.doi | 10.1016/j.celrep.2014.01.017 | es_ES |
dc.contributor.funder | Ministerio de Ciencia e Innovación (España) | |
dc.contributor.funder | Asociación Española Contra el Cáncer | |
dc.contributor.funder | Howard Hughes Medical Institute | |
dc.contributor.funder | Unión Europea. Comisión Europea. European Research Council (ERC) | |
dc.contributor.funder | Fundación Ramón Areces | |
dc.contributor.funder | Comunidad de Madrid (España) | |
dc.contributor.funder | Unión Europea | |
dc.contributor.funder | Worldwide Cancer Research | |
dc.contributor.funder | Cancer Research UK (Reino Unido) | |
dc.description.peerreviewed | Sí | es_ES |
dc.relation.publisherversion | https://doi.org/10.1016/j.celrep.2014.01.017 | es_ES |
dc.identifier.journal | Cell reports | es_ES |
dc.repisalud.institucion | CNIO | es_ES |
dc.repisalud.orgCNIO | CNIO::Grupos de investigación::Grupo de División Celular y Cáncer | es_ES |
dc.repisalud.orgCNIO | CNIO::Grupos de investigación::Grupo de Inestabilidad Genómica | es_ES |
dc.repisalud.orgCNIO | CNIO::Unidades técnicas::Unidad de Proteómica | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/SAF2011-23753 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/SAF2012-38215 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/FP7/210520 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/ES/S2010/BMD-2470 | es_ES |
dc.relation.projectID | info:eu_repo/grantAgreement/HEALTH-F5-2010-241548 | es_ES |
dc.rights.accessRights | open access | es_ES |